Welcome & Introduction

Transform the journey for your HER2+ Breast Cancer patients

ADVANCES IN THE MANAGEMENT OF LOCALIZED HER2 POSITIVE BREAST CANCER

Redefining the standard of care for postmenopausal HR+Her2-aBc

PIKing The Right Strategy in HR+Ve HER2-ve MBC

A Randomized Open Label Phase 3 study of Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy ALone in Patients

CAPMATINIB Unlocking The unMET need in METex14 skipping NSCLC

CLINICAL CASE

Lorlatinib in Management of ALK rearranged NSCLC

Long term survival outcomes with Nivolumab in mNSCLC

Optimizing Treatment for First-Line NSCLC

Weight Based Dosing of Immunotherapy

Closing Remarks